Skip to content
value.today

Zynex, Inc.

ZYXIUnlisted company
$366 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$192 M
For year ending December-2024
Net income
$3 M
1.6% margin
SEC filing
Employees
—

Zynex, Inc. in brief

Zynex, Inc. is an unlisted company in the Medical Devices industry, based in Englewood, Colorado, USA. It was founded in 1996. In the year to December 2024 it had sales of $192 M and a net profit of $3 M, about 2 cents of profit for every dollar of sales. Its largest product and service lines by sales in 2024 were Supplies (69%) and Device revenue (31%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Zynex, Inc.

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.

The company is based in unincorporated Douglas County, Colorado. Thomas Sandgaard serves as the company's CEO.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Zynex, Inc. timeline

10 events, 1999–2024
  1. 1999
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2000
  4. ✎
    Renamed Ibonzai Com Inc
    Formerly Life Medical Technologies Inc /Ut/.
  5. 2001
  6. 🏁
    · approximate
    Founded
  7. ✎
    Renamed China Global Development Inc
    Formerly Ibonzai Com Inc.
  8. 2003
  9. ✎
    Renamed Arizona Ventures Inc
    Formerly China Global Development Inc.
  10. ✎
    Renamed Fox River Holdings Inc
    Formerly Arizona Ventures Inc.
  11. 2004
  12. ✎
    Renamed Zynex Medical Holdings Inc
    Formerly Fox River Holdings Inc.
  13. 2008
  14. ✎
    Renamed Zynex Inc
    Formerly Zynex Medical Holdings Inc.
  15. 2021
  16. 💰
    Record net income of $17 million
    FY2021, the highest profit of the 7 years on record.
  17. 2024
  18. 💰
    Record revenue of $192 million
    FY2024, the highest of the 7 years on record.

Events of Zynex, Inc. from SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Zynex, Inc.

Acquisitions and changes
Delisted: it ended its SEC registration (Form 15) on 26 March 2026.

Market cap history

$0 M$144 M$287 M$431 M$575 M20202021202220232024

World rank over time

▲ up 152 places since 2020
2020-01-01: #14676#14,67620202021-01-01: #11486#11,48620212022-01-07: #15858#15,85820222022-12-25: #12004#12,00420222023-07-30: #14796#14,79620232024-01-05: #14524#14,5242024

Rank in USA: #3,036 (Jan 2020) · #2,806 (Jan 2021) · #3,329 (Jan 2022) · #2,540 (Dec 2022) · #3,006 (Jul 2023) · #2,782 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-68.4%
Operating margin
3.1%
Return on equity
-207.1%
Liabilities / assets
70.7%
Net debt
$-15M
Revenue growth
+4.4%
R&D / revenue
6.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $23M, net income $7M$23MFY17Fiscal year ending Dec 2018: revenue $32M, net income $10M$32MFY18Fiscal year ending Dec 2019: revenue $45M, net income $9M$45MFY19Fiscal year ending Dec 2020: revenue $80M, net income $9M$80MFY20Fiscal year ending Dec 2021: revenue $130M, net income $17M$130MFY21Fiscal year ending Dec 2022: revenue $158M, net income $17M$158MFY22Fiscal year ending Dec 2023: revenue $184M, net income $10M$184MFY23Fiscal year ending Dec 2024: revenue $192M, net income $3M$192MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$192M+4.4%$6M$3M1.6%
Dec 2023$184M+16.5%$11M$10M5.3%
Dec 2022$158M+21.4%$23M$17M10.8%
Dec 2021$130M+62.6%$22M$17M13.1%
Dec 2020$80M+76.2%$10M$9M11.3%
Dec 2019$45M+42.4%$11M$9M20.9%
Dec 2018$32M+36.2%$10M$10M29.9%
Dec 2017$23M—$9M$7M31.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$13M$1M$12M$0.09—
Dec 2023$18M$1M$17M$0.27—
Dec 2022$14M$0M$13M$0.44—
Dec 2021$7M$1M$6M$0.44—
Dec 2020$1M$1M$-0M$0.24—
Dec 2019$6M$0M$6M$0.28—
Dec 2018$9M$1M$8M$0.28—
Dec 2017$8M$0M$8M$0.22—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$108M
Net income, trailing 12 months
$-74M
RevenueNet income
Three months to Jun 2023: revenue $45M, net income $3M$45MJun ’23Three months to Mar 2024: revenue $47M, net income $0M$47MMar ’24Three months to Jun 2024: revenue $50M, net income $1M$50MJun ’24Three months to Sep 2024: revenue $50M, net income $2M$50MSep ’24Three months to Dec 2024 (from the annual report): revenue $46M, net income $-1M$46MDec ’24Three months to Mar 2025: revenue $27M, net income $-10M$27MMar ’25Three months to Jun 2025: revenue $22M, net income $-20M$22MJun ’25Three months to Sep 2025: revenue $13M, net income $-43M$13MSep ’25

Latest quarter to Sep 2025: revenue $13M (-73.3% on a year earlier), net income $-43M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2025.

SEC filings

Official filings of Zynex, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$192 M
Operating income
$6 M
Net income
$3 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$122 M
Total liabilities
$86 M
Total equity
$36 M

As of December-2024

Insider trading at Zynex, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
8
since
$58 K-$260 K$0Jul 2024: bought $58 K (1 trades), sold $124 K (1 trades)Jul 24Aug 2024: bought $0 (0 trades), sold $199 K (2 trades)AugOct 2024: bought $0 (0 trades), sold $35 K (2 trades)OctNov 2024: bought $0 (0 trades), sold $260 K (11 trades)NovDec 2024: bought $0 (0 trades), sold $81 K (1 trades)DecJan 2025: bought $0 (0 trades), sold $79 K (1 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $77 K (1 trades)FebMar 2025: bought $0 (0 trades), sold $72 K (1 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Zynex, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joshua R. DisbrowDirectorDisposal to the company-12,499——0Form 4
filed Michael D. CressDirectorDisposal to the company-12,499——0Form 4
filed Barry D. MichaelsDirectorDisposal to the company-80,001——0Form 4
filed Joshua R. DisbrowDirectorDisposal to the company-89,501——0Form 4
filed Michael D. CressDirectorDisposal to the company-82,501——0Form 4
filed Anna LucsokCHIEF OPERATING OFFICERShares withheld for tax-3,793$2.560$10 K40,856Form 4
filed Anna LucsokCHIEF OPERATING OFFICERGrant or award+7,500——64,412Form 4
filed Daniel J. MoorheadCHIEF FINANCIAL OFFICERShares withheld for tax-3,982$2.130$8 K16,273Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Zynex, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-12-15
3.6 M
11.4% of shares · 2.42 days to cover
Buybacks, Q3 2025
$0M
Q3 2025
Shares sold short, last 24 reportsAll stocks →

Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K); (8-K)

Zynex, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0M
Q1 2025Q1 2025$4.9M
Q4 2024Q4 2024$0M
Q3 2024Q3 2024$0M
Q2 2024Q2 2024$2.3M
Q1 2024Q1 2024$13.3M
Q4 2023Q4 2023$13.5M
Q3 2023Q3 2023$14.9M
Q2 2023Q2 2023$6.1M
Q1 2023Q1 2023$3.4M
Q4 2022Q4 2022$6.6M
Q3 2022Q3 2022$9.2M
Q4 2021Q4 2021$0M
Q3 2021Q3 2021$0.5M
Q2 2021Q2 2021$2M

Trading halts

  • 2025-11-26 19:58 UTC, code LUDP, resumed 20:03 UTC
  • 2025-11-26 19:42 UTC, code LUDP, resumed 19:47 UTC
  • 2025-11-26 18:49 UTC, code LUDP, resumed 18:54 UTC

Fails to deliver

  • : 2.6 M shares at $0.13
  • : 15,831 shares at $0.19
  • : 139,620 shares at $0.29
  • : 75,763 shares at $0.28
  • : 70,506 shares at $0.26

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Zynex, Inc. scorecard#

Passes 12 of the 17 checks that could be worked out: strongest in shareholder returns (3 of 4), weakest in profitability (3 of 5). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year4.4%Revenue up 4.4% in fiscal 2024.
    • ✓Revenue up more than 5% a year over three years13.9%13.9% a year over the three years to fiscal 2024.
    • ✓Faster growth over three years than its peers' median13.9%13.9% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year0.09 vs 0.27Diluted EPS 0.09 in fiscal 2024 against 0.27 the year before (report's currency).
    • ✗Net income higher than five years earlier$3 M$3 M in fiscal 2024 against $9 M in 2019.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
  • Profitability3 of 5
    • ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2024.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2024.
    • ✓Operating margin above its peers' median3.1%3.1% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%7.3%7.3% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier3.1%3.1% in fiscal 2024 against 17.2% in 2021.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities4.5×Current ratio 4.46 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns3 of 4
    • ✓Pays a dividendYesPaid dividends in fiscal 2024.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✓Dividends under 75% of net income0.3%Dividends were 0.3% of net income in fiscal 2024.
    • ✓Share count up no more than 2% in a year-10.6%Diluted shares down 10.6% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • ✗Free cash flow covers dividends and buybacks$12 MFree cash flow $12 M against $16 M paid out in fiscal 2024.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Zynex, Inc.'s statements, beside the median of Medical Devices.

Zynex, Inc.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin3.1%-8.2%
Net margin1.6%-10.4%
Return on equity7.3%-16.8%
Revenue growth, 3 years a year13.9%10.8%
Revenue growth4.4%10.4%
Free cash flow margin6.3%-1.9%

6of 8on the Piotroski tests of financial strength

  • Revenue has grown 10 years in a row.
  • The share count fell 10.6% in the year (buybacks).

Zynex, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Zynex, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue192184158130804532231312
Cost of revenue39383227178.86.04.83.54.9
Research and development129.27.12.60.80.60.20.10.3r0.3
Selling, general and administrative——————169.79.29.2
Selling and marketing878767543415r6.5———
General and administrative604936261811r9.0———
Total costs and expenses1861741351087034221413—
Operating income6.01123221011108.90.6−2.5
Interest expense and finance costs——————0.21.50.40.5
Net interest income—−1.1−0.4−0.1−0.0−0.0−0.2———
Other non-operating income (expense)−2.41.8−0.7−0.1−0.10.9−0.2−1.5−0.6−0.5
Income before tax3.61322221012107.50.1−3.0
Income tax0.62.85.25.21.12.40.70.10.0−0.1
Net income including minority interests3.09.717179.19.59.67.40.1−2.9
Minority interests' share of net income——————000−0.0
Net income attributable to shareholders3.09.717179.19.59.67.40.1−2.9
Earnings per share, basic0.090.270.440.450.24r0.290.290.230.00-0.09
Earnings per share, diluted0.090.270.440.440.24r0.280.280.220.00-0.09
Shares, weighted average (basic)3236383837r32333231r31
Shares, weighted average (diluted)3236393938r34343331r31
Balance sheet
Cash and cash equivalents404520433914105.60.20.0
Short-term investments0—————————
Receivables18273529145.82.82.23.02.4
Inventory141313118.62.40.80.40.10.3
Other current assets3.63.30.90.71.40.30.6r0.2——
Current assets75887083632314r8.43.42.8
Property, plant and equipment3.13.12.22.21.90.90.80.20.60.8
Right-of-use (leased) assets9.81313166.03.83.1r———
Goodwill20202020r——————
Other intangible assets7.28.29.1r10.0———00.00.1
Total assets122137116133722819r8.94.13.7
Accounts payable7.18.45.6r4.74.7r2.1r1.62.3r2.92.5
Debt due within a year——5.35.3——————
Current liabilities17192123105.27.0r4.0r7.77.5
Long-term debt——5.311——————
Lease liabilities (non-current)101414164.93.33.0———
Total liabilities86915059158.610.0r4.07.97.8
Retained earnings302717023144.9r−2.4−9.8−9.8
Shareholders' equity3646667457209.4r5.0−3.7−4.0
Minority interests—————−0.1−0.1−0.1−0.1−0.1
Total equity———7457209.3r4.9−3.8−4.1
Total liabilities and equity122137116133722819r8.94.13.7
Shares outstanding3233374038r3332333131
Cash-flow statement
Share-based compensation3.02.32.31.62.70.80.40.10.20.1
Cash from operating activities1318146.90.86.39.48.31.80.3
Capital expenditure−0.6−1.2−0.4−0.6−1.0−0.2−1.1−0.1−0.2—
Acquisitions, net of cash acquired———−16——————
Cash from investing activities−0.6−1.0−0.4−17−1.0−0.2−1.1−0.1−0.20.1
Debt issued———16——————
Debt repaid—−11−5.3———————
Shares issued————250.20.20.00—
Shares bought back−16−38−26−2.7—−0.2−3.4−0.20—
Dividends paid−0.0−0.0−3.6−0.0—−2.3————
Cash from financing activities−177.6−361325−2.2−3.8−2.9−1.3−0.5
Change in cash−4.924−223.4253.94.65.30.2−0.1
Report10-K/A10-K/A10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Zynex, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2023. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Supplies$133 M69%
  • Device revenue$60 M31%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Events at Zynex, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipFiling
  • Bankruptcy or receivershipFiling
  • Bankruptcy or receivershipFiling
  • Bankruptcy or receivershipFiling
  • Bankruptcy or receivershipDelisting noticeFiling
  • Bankruptcy or receivershipDebt called earlyFiling

And 2 more in the list below.

Bankruptcy or receivership 6 · Delisting notice 1 · Auditor changed 1 · Debt called early 1 · Impairment 1 · Restructuring 1 · Change in control 1 · Directors and officers 8 · Material agreement 5 · Agreement ended 1 · New debt 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6

Zynex, Inc.: events reported to the SEC
FiledWhat happenedFiling
Change in controlDirectors and officersMaterial agreementAgreement endedNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Bankruptcy or receivership8-K
Material agreement8-K
Bankruptcy or receivership8-K
Bankruptcy or receivership8-K
Directors and officers8-K
Bankruptcy or receivershipMaterial agreementNew debt8-K
Bankruptcy or receivershipDelisting noticeMaterial agreementNew debt8-K
Bankruptcy or receivershipDebt called earlyMaterial agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
ImpairmentRestructuring8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Mar 26, 2026

Layoffs at Zynex, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
86
2025–2025
Latest
—
2025-10-01
Zynex, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025·····86······86
Zynex, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
86 peopleRestructuring planSEC 8-K“(the “Company”) executed a reduction in its workforce affecting 86 corporate roles, or 14% of the Company’s total number of employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Zynex, Inc. compares in Medical Devices

  • Revenue$192 M · higher than 53% of 155
  • Net margin-68.3% · higher than 20% of 144
  • Revenue growth4.4% · higher than 31% of 104

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Zynex, Inc.🇺🇸$366 M—-68.3%+4.4%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Zynex, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Zynex, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Zynex, Inc.? Suggest a correction